Sign up for Table of Contents Alerts.
Email this page
Print this page
Research Paper
Development of Ad-mda7/IL-24-resistant lung cancer cell lines
Abujiang Pataer, Sunil Chada, Jack A. Roth, Kelly K. Hunt and Stephen G. Swisher
volume 7 | issue 1
January 2008Pages: 103 - 108
Subscribe to this journal for $129/year
Many cancers can become resistant to repeated administration of even the most effective therapeutic agents. In developing adenoviral mda-7/IL-24 (Ad-mda-7/IL-24) therapy for lung cancer, we have anticipated this potential clinical problem by attempting to identify the molecular mechanisms of Ad-mda7/IL-24 resistance in several Ad-mda7/IL-24-resistant lung cancer cell lines that we have developed. For the present study, we established four Ad-mda7-resistant cell lines by repeated selection of resistant clones of parental Ad-mda7-sensitive A549 cells: two lines (A549R1 and A549R2) resistant to both adenoviral vector and the mda-7 gene and two (A549R3 and A549R4) resistant to the therapeutic mda-7 gene only. As shown by western blot analysis of several known anti-apoptotic proteins, parental A549 and resistant A549R3 cells expressed similar levels of AKT and phosphorylated AKT (p-AKT), whereas resistant A549R3 and A549R4 cells expressed higher levels of bcl-2 and lower levels of bcl-xL than did their parental cells. As shown by flow-cytometric analysis, treating resistant A549R3 and A549R4 cells with a combination of Ad-mda7 and 17-allylamino-17-demethoxygeldanamycin (17AAG) (50 nM) for 48 hours enhanced apoptosis. Together, these in vitro findings indicate that an antiapoptotic mechanism may underlie Ad-mda7 resistance and that such resistance can be overcome by addition of 17AAG. Further investigations along these lines are warranted.
Authors
Abujiang Pataer
The University of Texas M. D. Anderson Cancer Center, Houston, TX
Sunil Chada
The University of Texas M. D. Anderson Cancer Center, Houston, TX
Jack A. Roth
The University of Texas M. D. Anderson Cancer Center, Houston, TX
Kelly K. Hunt
The University of Texas M. D. Anderson Cancer Center, Houston, TX
Stephen G. Swisher
The University of Texas M. D. Anderson Cancer Center